COR
Cencora, Inc. Health Care Wholesale-Drugs, Proprietaries & Druggists' Sundries S&P 500Russell 3000
$330.84Close
$64.2BMarket cap
$251.67 – $372.5352-week range
Nov 4, 2026Next report · before the open
Highlights
Cautions
- Not in an uptrend 5 of 8 trend conditions
- Results soon Nov 4, 2026, in 3 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
11%
1wk
0.0%
price change
1mo
up 10.2%
price change
12-month return
down 2%
market up 11% ·
its own down 11%
F-score
7 / 9
Strong
Altman Z″
0.05
Elevated risk
P/E
41.3×
price / earnings
PEG
7.29
P/E / EPS growth
P/B
42.5×
price / book
Earnings yield
up 3.9%
EBIT / enterprise value
Cheaper than
41%
of the market · around average
Revenue growth
up 9%
year on year
EPS growth
up 12%
latest quarter · -116 pts
Sales growth
up 5%
latest quarter · +1 pts
ROE
up 144%
return on equity
Free cash margin
up 1%
$3.2B FCF
D/E
5.00
long-term debt / equity
Net debt / EBITDA
0.9×
Interest cover
—EBIT / interest
Piotroski tests
- profitability slipped from last year
- took on more long-term debt
- profitable on its assets
- generating cash from operations
- profits backed by cash
- short-term liquidity improved
- no new shares issued
- gross margin widened
- assets working harder
Trade setup
ATR%
2.2%
$7.15 a day · 2×ATR $316.55
RS
50 / 99
vs the universe
Trend
5 / 8
150-day under the 200-day, 200-day not rising, RS under 70
Relative volume
1.1×
vs 50-day average
Up/down volume
0.85
50 sessions
Implied move
8.7%
by Nov 20, 2026 · report Nov 4, 2026
Trend template · 5 of 8
- Price above the 150 and 200-day averages: passes
- 150-day average above the 200-day: fails
- 200-day average rising for a month: fails
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: passes
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: passes
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
Last reported
Oct 21, 2026
Results reaction
Oct 21, 2026-1% vs market2 sessions after results
Options
$212,44040.3% IV · activity
Financials
- Gross 4%
- Net 0%
- Free cash 1%
- Cash
- Long-term debt
| FY2020Sep 30, 2020 | FY2021Sep 30, 2021 | FY2022Sep 30, 2022 | FY2023Sep 30, 2023 | FY2024Sep 30, 2024 | FY2025Sep 30, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $189.9B | $214.0B | $238.6B | $262.2B | $294.0B | $321.3B |
| Gross margin | 3% | 3% | 3% | 3% | 3% | 4% |
| Operating income | -$5.1B | $2.4B | $2.4B | $2.3B | $2.2B | $2.6B |
| Net income | -$3.4B | $1.5B | $1.7B | $1.7B | $1.5B | $1.6B |
| Net margin | -2% | 1% | 1% | 1% | 1% | 0% |
| Earnings per share | -$16.65 | $7.39 | $8.04 | $8.53 | $7.53 | $7.96 |
| Free cash flow | $1.8B | $2.2B | $2.2B | $3.5B | $3.0B | $3.2B |
| Free cash margin | 1% | 1% | 1% | 1% | 1% | 1% |
| Cash | $4.6B | $2.5B | $3.4B | $2.6B | $3.1B | $4.4B |
| Long-term debt | $3.6B | $6.4B | $4.6B | $4.1B | $3.8B | $7.5B |
| Shareholders' equity | -$1.0B | $223.4M | -$211.6M | $522.0M | $645.9M | $1.5B |
| Shares outstanding | 204.23m | 208.09m | 206.20m | 200.81m | 194.94m | 193.94m |
Next report
Nov 4, 2026 · before the open
Expected move The move, either way, the option market prices in through the next scheduled report: the at-the-money straddle for the first expiry that contains it, over the price. It includes the days around the report, so it slightly overstates the report alone. Methodology
±8.7%
$302 – $360 by Nov 20, 2026
Usual move The median, over the company's last four reports, of how far the stock moved either way from the close before the filing to the close of the session after it. Methodology
±4.4%
last 4: -1.4% · +6.1% · -16.4% · -2.7%
Expected against usual The move the options price through this report over the move the last four reports delivered. Above 1 the event is priced bigger than the company's own record; below 1, smaller. A price, not a forecast: it says what protection through the report costs, not which way the stock will go. Methodology
Bigger than usual
2.0× the usual move
What options price now
- Swings expected vs recent The daily swings the options are priced for (implied volatility) against the swings the stock actually had over the last 20 sessions (realised volatility). Bigger means options charge for more movement than the stock has been delivering; smaller, less. On a contract row, that contract's own implied volatility over the stock's realised. Methodology
- Bigger 40.3% priced · 18.1% recent
- Next month vs later At-the-money implied volatility for 8-45 day expiries over 46-90 day ones: whether options price the coming month as choppier or calmer than the two after it. Ahead of a report it usually reads choppier, and the extra comes out once the report is out. Methodology
- Choppier
- Crash protection What options that pay off in a fall cost against options that pay off in a rise (the 25-delta skew), compared with this company's own normal - the median of its stored nightly readings, once there are 20 - and with five sessions ago. Protection costs a little more than upside on most shares. More than usual means readers of the chain are paying up to insure against a drop; it does not say which way the stock will go. Methodology
- past week: costs less
Positioning
- Premium traded
- $212,440 calls $146,432 · puts $66,008 · latest session
- 0.45× +0.32 over the week
- Open interest added The change over five sessions in option positions left open overnight, calls and puts. A rise means positions were added. It cannot say whether they were bought or sold, so more calls is not a vote for a rise: a call is as often sold against shares already held. Methodology
- calls +205 · puts +888 past week
For options traders: ATM IV 40.3% (+5.8% 1w) · 1m ÷ 3m IV 1.29 · 25Δ skew 1.7 pts · Net GEX $2.3M
Most traded contracts
No contract passed the liquidity filters this week.
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Feb 4, 2026 | Quarterly ↗ | Dec 31, 2025 | 35d |
| Nov 25, 2025 | Annual ↗ | Sep 30, 2025 | 56d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 7, 2025 | Quarterly ↗ | Mar 31, 2025 | 37d |
| Feb 5, 2025 | Quarterly ↗ | Dec 31, 2024 | 36d |
| Nov 26, 2024 | Annual ↗ | Sep 30, 2024 | 57d |
| Jul 31, 2024 | Quarterly ↗ | Jun 30, 2024 | 31d |
| May 1, 2024 | Quarterly ↗ | Mar 31, 2024 | 31d |
| Jan 31, 2024 | Quarterly ↗ | Dec 31, 2023 | 31d |
| Nov 21, 2023 | Annual ↗ | Sep 30, 2023 | 52d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 21, 2026 | Results · Regulation FD ↗ |
| Sep 25, 2026 | Director or officer change · Regulation FD ↗ |
| Aug 14, 2026 | Director or officer change ↗ |
| Aug 12, 2026 | Regulation FD ↗ |
| Aug 5, 2026 | Results · Regulation FD ↗ |
| Aug 5, 2026 | Material agreement · New obligation ↗ |
| Jun 15, 2026 | Director or officer change · Regulation FD ↗ |
| May 29, 2026 | Director or officer change · Regulation FD ↗ |
| May 6, 2026 | Results · Regulation FD ↗ |
| Mar 23, 2026 | Regulation FD ↗ |
| Mar 17, 2026 | Director or officer change · Regulation FD ↗ |
| Mar 6, 2026 | Shareholder vote ↗ |